Good day, and welcome to the Vertex Pharmaceuticals fourth quarter ... Susie Lisa-- Senior Vice President, Investor Relations Good evening, all. My name is Susie Lisa. And as the senior vice ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

In early Mongolia, herders dismantle their yurt - a portable round tent made of felt or animal skin - in pursuit of new lands where they can raise their livestock. Not much further away is a ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. This publication aims to provide Member States with a ...

For the past 8 years, I've covered all things shopping. My work's been published by Hearst, PureWow, and Bauer Media Group. I'm a Brooklyn-born Jersey Girl (with a BA in English from Montclair State ...